Llwytho...
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This artic...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Cosmet Investig Dermatol |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6503649/ https://ncbi.nlm.nih.gov/pubmed/31118733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CCID.S165605 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|